- Home
- NVT vs NBIX Comparison
NVT vs NBIX Comparison
Compare NVT & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVT
- NBIX
- Stock Information
- Founded
- NVT 1903
- NBIX 1992
- Country
- NVT United Kingdom
- NBIX United States
- Employees
- NVT N/A
- NBIX N/A
- Industry
- NVT Industrial Machinery/Components
- NBIX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NVT Industrials
- NBIX Health Care
- Exchange
- NVT Nasdaq
- NBIX Nasdaq
- Market Cap
- NVT 12.0B
- NBIX 11.8B
- IPO Year
- NVT N/A
- NBIX 1996
- Fundamental
- Price
- NVT $77.92
- NBIX $125.00
- Analyst Decision
- NVT Strong Buy
- NBIX Buy
- Analyst Count
- NVT 6
- NBIX 24
- Target Price
- NVT $85.33
- NBIX $163.91
- AVG Volume (30 Days)
- NVT 2.2M
- NBIX 1.1M
- Earning Date
- NVT 11-01-2024
- NBIX 10-30-2024
- Dividend Yield
- NVT 0.97%
- NBIX N/A
- EPS Growth
- NVT 21.96
- NBIX 97.40
- EPS
- NVT 3.42
- NBIX 3.73
- Revenue
- NVT $3,539,100,000.00
- NBIX $2,242,800,000.00
- Revenue This Year
- NVT $0.29
- NBIX $26.97
- Revenue Next Year
- NVT $5.74
- NBIX $16.69
- P/E Ratio
- NVT $22.77
- NBIX $33.47
- Revenue Growth
- NVT 30.11
- NBIX 25.72
- 52 Week Low
- NVT $52.26
- NBIX $110.52
- 52 Week High
- NVT $86.57
- NBIX $157.98
- Technical
- Relative Strength Index (RSI)
- NVT 59.54
- NBIX 57.39
- Support Level
- NVT $72.42
- NBIX $115.27
- Resistance Level
- NVT $76.88
- NBIX $129.67
- Average True Range (ATR)
- NVT 2.46
- NBIX 3.37
- MACD
- NVT 0.00
- NBIX -0.09
- Stochastic Oscillator
- NVT 91.28
- NBIX 67.57
About NVT nVent Electric plc
nVent is a leading global provider of electrical connection and protection solutions that touches a broad range of end markets including infrastructure, industrial, commercial, and residential. NVent designs, manufacturers, markets, installs, and services a portfolio of electrical enclosures and electrical fastening solutions. nVent currently has three reportable segments: Enclosures, Electrical & Fastening Solutions, and Thermal Management. Thermal Management is expected to be sold by early 2025. North America accounts for the majority of sales.
About NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.